RxDoctor Payments Data

Mark Wilkinson, MD

Gastroenterology · Lewes, DENPI 1326235623

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 20 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by Boston Scientific at 47.4% of the total. Reporting peaked in 2024 at $312 and has fallen 52.0% since, to $150 in 2025. That places this record below the midpoint for gastroenterology clinicians in DE, where the typical reported total is $2,631.

$705in general payments, 2019–2025

Across 20 payments — averaging $35.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$334
  • Olympus America Inc.$223
  • Ambu Inc.$86
  • Johnson & Johnson$31
  • Medtronic$17
  • Braintree Laboratories, Inc.$13

What the payments were for

  • Food & beverage$705100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$705 in reported general payments places this provider in the 20th percentile of 50 gastroenterology providers in Delaware.

See all gastroenterology providers in Delaware

Medicare billing

Part B allowed, 2024
$211,382
Medicare patients
867
Services billed
1,532

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide24$21,423
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates202$12,581
SutabSod Sulf/Pot Chloride/Mag Sulf19$3,044
Pantoprazole Sodium133$2,576
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C17$2,408
ClenpiqSod Picosulf/Mag Ox/Citric Ac11$1,884
Omeprazole113$1,830
Esomeprazole Magnesium31$1,265
Famotidine56$741
Sucralfate23$682
Ondansetron OdtOndansetron23$385
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl18$319
Dicyclomine Hcl14$202

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Braintree Laboratories, Inc.Sutab$13$3,04419 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 50 gastroenterology providers in Delaware.

Other gastroenterology in Lewes

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →